Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3164 results found
Expand All
Apply All
3164 results found

BIO Membership Compact & Social Responsibilities
Share
To be eligible for membership in BIO, a firm or organization must fit into one of the membership categories outlined in BIO’s bylaws (i.e., Core, Associate, Affiliate, and Center members). Further, membership in BIO is open only to firms or organizations that generally support BIO’s public policy positions, and whose own positions and business practices are generally consistent with BIO’s reputation and its policies and principles in support of innovation, including intellectual property rights. As part of the application and membership renewal process, each firm or organization is required to affirm that it meets such criteria.As an indicium of a Core Member’s “support for innovation,” an important criterion includes an assessment of whether a Core Member company invests significantly in innovative (i.e., new and novel) biotechnological research and development (R&D) activities.Beyond these core requirements of membership, BIO expects that its members will not engage in conduct that is detrimental to the purpose or reputation of the organization.BIO Statements and Principles regarding Biotech Social Responsibilities:In addition to BIO’s membership criteria, BIO’s Board of Directors has, over the years, adopted a series of official Statements and Principles that help to set expectations regarding the social responsibilities of our members and the broader biotechnology community, and to encourage societally beneficial conduct. While non-exhaustive, we have provided below the links to some of the most important Statements and Principles adopted by BIO’s Board.Statement of BIO Ethical PrinciplesPrinciples on Protecting Research and Research ParticipantsPrinciples on Responsible Sharing of Truthful and Non-Misleading Information About Medicines With Health Care Professionals and PayersStatement of Ethical Principles for the Care and Use of Animals in Biotechnology ResearchStatement on the Ethical Use of Biotechnology to Promote Public Health and National Security…
Read More

Senior Leadership Team at BIO
Share
Meet the leaders behind the Biotechnology Innovation Organization.
Read More

Reauthorizing the PRV
Share
Policy
prv

Lab Equipment Service Contract Consolidation
Share
BIO Business Solutions - Program
About SU GroupSpecialty Underwriters (SU Group) delivers a customized equipment maintenance solution that streamlines contract management while reducing costs. By consolidating service contracts into one agreement, SU Group provides budget predictability, convenience, and flexibility — ensuring equipment stays covered without the administrative burden of managing multiple vendors.For life sciences companies, SU Group’s coverage spans a wide range of categories, including:General laboratory equipmentMolecular biologyProtein analysisGenomics & proteomicsClinical & R&D lab equipmentCell biology instrumentsImaging & microscopyBiochemical analysisThrough BIO Business Solutions®, member companies receive exclusive discounts and consolidated service solutions, helping them control costs while keeping critical equipment operational.
Read More

Business Insurance Carrier (P&C, Clinical Trial, Product)
Share
BIO Business Solutions - Program
About ChubbChubb is a global leader in business insurance carrier and has been BIO’s endorsed insurance partner for more than 25 years. With specialized expertise in biotechnology and life sciences, Chubb delivers cost-effective risk management and protection designed for companies advancing innovation at every stage.For life science organizations, Chubb provides comprehensive coverage solutions including property and casualty, product liability, clinical trial liability, errors and omissions, professional liability, and cyber insurance*. Chubb’s team understands the specific risks of the biotech sector and develops tailored solutions to address them.Through BIO Business Solutions®, member companies benefit from exclusive premium credits and specialized support, helping them safeguard operations, maintain compliance, and scale with confidence.*The BIO-Chubb cyber liability insurance offering is for new business only.
Read More

Lab Supplies & Solutions
Share
BIO Business Solutions - Program
About VWR, part of AvantorVWR, part of Avantor is a global leader in life sciences and advanced technologies, delivering laboratory products, production supplies, and services used across pharmaceutical, biotechnology, industrial, education, government, and healthcare organizations.For life science companies, VWR provides reliable access to everything from everyday consumables to complex capital equipment — supporting innovation from early-stage R&D through large-scale manufacturing.Through BIO Business Solutions®, member companies gain access to VWR's national contract, unlocking deep discounts, exclusive rebates, and flexible pricing options designed specifically for the life sciences community. VWR, part of Avantor has been BIO’s preferred partner since 1997, making it one of the longest-running and most impactful programs in the portfolio.
Read More

Inquiry Form for VWR, part of Avantor
Share
BIO Business Solutions
BIO Business Solutions® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual sales, BIO Business Solutions® aggregates the purchasing power of over 4,700 life science companies from North America. Companies of all sizes save substantial money each year through this cost-savings program.To request information for the BIO-VWR Program, please fill the fields below and click the Submit button at the bottom of the form. MktoForms2.loadForm("//app-ab15.marketo.com", "490-EHZ-999", 3825);
Read More

Letter From BIO President & CEO John F. Crowley to Senate and House Leadership on GLOBE GUARD
Share
Letters, Testimony & Comments  •  February 9, 2026
Dear Mr. Thune, Mr. Schumer, Mr. Johnson, and Mr. Jeffries:As President and CEO of the Biotechnology Innovation Organization (BIO), as a father and entrepreneur whose family is here today because of biotech innovation, and on behalf of the more than 1,000 innovative companies we represent, I write to express our significant concerns with the "Global Benchmark for Efficient Drug Pricing" (GLOBE) and "Guarding U.S. Medicare Against Rising Drug Costs" (GUARD) mandatory demonstration models recently released by the Center for Medicare and Medicaid Innovation (CMMI).Though these "Most Favored Nation"-like models purport to make medicines more affordable for American patients – a worthy and necessary goal – the proposed demos will eviscerate the innovation pipeline and risk jeopardizing patient access to the next generation of medicines. We respectfully implore Congress to urge CMS to rescind these models and to prevent any effort to codify Most Favored Nation policies into law.At a time when affordability is critical to Americans, we encourage you instead to pursue bipartisan legislative reforms to simplify the system and deliver more affordable medicines to patients without jeopardizing America's world-leading biotech industry and the millions of jobs and trillions in economic activity it supports.Mandatory Demonstration Models & Their ImpactThe GUARD and GLOBE mandatory demonstration models will upend many biotech companies and undermine America's biotech industry as a whole, especially threatening the small and mid-sized companies that develop over half of all new drugs. Many biotech innovators have only one or a small handful of products, while numerous others have only a single experimental therapy in development and bring in little to no revenue at all. This makes them especially reliant on private investment to survive.The Real Story of the Biotech Innovation RevolutionThe process of bringing a drug to market is fraught with risk and failure. As someone who…
Read More

BIO marks wins on PPRV, PBMs
Share
Good Day BIO Newsletter  •  February 9, 2026
BIO celebrates passage of PPRV reauthorization and PBM reform. Also, new legislation would help fight AMR. (943 words, 4 minutes, 42 seconds) Because Feb. 16 is Presidents Day, our next newsletter comes out Tuesday, Feb. 17.
Read More

How Vaccines Fight Disease
Share
Human Health, Biodefense and Vaccines  •  Toolkit  •  February 9, 2026
Declining immunization rates in the United States leave us vulnerable to infection from vaccine-preventable diseases. For example, in only the first three months of 2025, there have already been more measles cases in the U.S. than in all of 2024.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 7
  • 8
  • 9
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO